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REVIEW

Exercise Medicine in the Management of Pancreatic Cancer
A Systematic Review
Hao Luo, MEd,*† Daniel A. Galvão, PhD,*† Robert U. Newton, PhD,*†‡ Pedro Lopez, MSc,*†
Colin Tang, MBBS,*†§ Ciaran M. Fairman, PhD,*†
Nigel Spry, MBBS, PhD,*†|| and Dennis R. Taaffe, PhD, DSc, MPH*†
Downloaded from https://journals.lww.com/pancreasjournal by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 06/07/2021

Abstract: The aim of this study was to examine the health-related effects
of exercise in patients with pancreatic cancer (PanCa) through a systematic review of current evidence. Studies were obtained through searching
PubMed, Web of Science, PsycINFO, Embase, CINAHL Plus, and Cochrane
Library databases with additional hand searches. All intervention-based
studies were included if it involved (1) adult patients with PanCa, (2) exercise training, and (3) findings in quality of life, cancer-related fatigue, psychological distress, and physical function. The review protocol was
registered in PROSPERO: CRD42020154684. Seven trials described in
9 publications were included consisting of 201 patients with early-stage
and advanced PanCa. Participants were required to perform supervised
and/or home-based, low- to moderate-intensity resistance and/or aerobic
exercise for 12 to 35 weeks or duration of neoadjuvant therapy. There were
no exercise-related adverse events with a reported retention rate of 71% to
90% and exercise attendance of 64% to 96%. The programs were consistently associated with improvements in cancer-related fatigue, psychological distress, and physical function, with mixed effects on quality of life.
Exercise training seems to be safe and feasible and may have a beneficial
effect on various physical and psychological outcomes in patients with
PanCa. Further work with rigorous study designs is required to consolidate
and advance current findings.
Key Words: pancreatic cancer, exercise, quality of life, cancer-related
fatigue, psychological distress, physical function
(Pancreas 2021;50: 280–292)

P

ancreatic cancer (PanCa) remains one of the most aggressive
malignancies with a 5-year survival rate ranging from 5% to
15%1 and a rising incidence rate globally.2,3 Current treatment options for PanCa including surgery, chemotherapy, and radiotherapy
provide limited survival benefits yet impose considerable physical
and psychological burden. Patients with PanCa during and after
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treatments are predisposed to experience loss of skeletal muscle
mass, impaired physical function, and increased fatigue and psychological distress.4–9 In addition, PanCa is typically diagnosed
in patients at an older age (median age, ~70 years) and with advanced disease.3,10 Comorbidities such as sarcopenia and cachexia are prevalent in patients with PanCa,11,12 along with
various other debilitating symptoms including pain, insomnia,
vomiting, and nausea.13,14 These health conditions resulting from
PanCa treatments and the disease can severely compromise patients'
physical functioning and overall quality of life (QoL).10,15,16 Given
the relatively short survival time in patients with PanCa after diagnosis (median survival, ~3–26 months),10,17 QoL is of paramount
importance and is an independent predictor of overall survival.16,18,19 Therefore, strategies that enhance QoL and attenuate
decline in physical and psychological function in this patient group
are of clinical importance.
Exercise training is increasingly recognized as an effective
therapy for patients after cancer diagnosis across the disease spectrum, improving quality and, possibly, quantity of life; reducing
treatment side effects; enhancing fitness and health in preparation
for surgery and other treatments; and rehabilitating function and
structure after treatment. Numerous systematic reviews and
meta-analyses indicate that regular exercise can result in improvements in QoL, physical function, cancer-related fatigue (CRF) and
psychological health in patients with cancer before, during, and
after treatment.20–24 In addition, exercise (in particular resistance
training) is recommended as an essential intervention component
to treat cancer cachexia.25 Initial evidence suggests that individualized exercise interventions can be well accepted by patients with
cancer (including PanCa) with cachexia or in the precachexia
stage and is associated with promising efficacy on body mass
when delivered concomitantly with nutritional support and
anti-inflammatory medications.26,27 The substantial benefits of
exercise in patients with cancer have prompted the development
of various international guidelines28–30 recommending patients
with cancer to stay physically active according to their clinical
needs, personal circumstances, and preferences. However, most
patients involved in current exercise oncology research are diagnosed with common types of solid tumors including breast, prostate, lung, and colorectal, and with early-stage disease.31
A small but growing number of exercise trials in patients
with PanCa have been published; however, to date, the research
findings regarding the health-related effects of exercise in this patient group have not been systematically appraised and synthesized. Although a recent systematic review32 has discussed the
effects of exercise on physical function and physical activity level
in patients with resectable or potentially resectable liver and pancreatic tumors, only 2 experimental studies in patients with PanCa
were included. In addition, the effects of exercise on other important health-related outcomes that commonly deteriorate as a result
of PanCa and its treatments have not been addressed, including
QoL, CRF, and psychological distress.
Pancreas • Volume 50, Number 3, March 2021

Pancreas • Volume 50, Number 3, March 2021

Therefore, we conducted a systematic review to examine the
health-related effects of exercise training in patients with PanCa.
The primary end point was the reported change in QoL outcomes
measured at different follow-up periods. In addition, the effects of
exercise training on CRF, psychological distress, and objectively
measured physical function (including muscle strength, cardiovascular fitness, functional ambulation, and balance) were also evaluated.
When available, the magnitude of change in the outcome measure
was checked for clinical meaningfulness based on an established
minimal important difference (MID) (Supplemental Table 1,
http://links.lww.com/MPA/A854).

MATERIALS AND METHODS
This review was conducted and reported following the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guidelines,33 and the review protocol was registered with the International Prospective Register of Systemic Reviews (PROSPERO ID: CRD42020154684).

Exercise Medicine for Pancreatic Cancer

to ensure further identification of eligible studies. For example, the
reference lists of identified original studies and reviews were
checked. Moreover, publication alerts were set up in PubMed in
October 2019 using MeSH terms (ie, pancreatic neoplasms) and 2
groups of free-text terms for population and intervention, respectively.

Selection Strategy
Records yielded from electronic searching were exported and
stored in EndNote (X9.3.2, Clarivate, London, UK). Duplicates
were removed either automatically (using EndNote) or manually.
After deduplication, the titles and abstracts of the remaining records
were first reviewed by H.L. to exclude irrelevant articles. Subsequently, peer-reviewed journal articles with full text and published
in English were further reviewed by H.L. and D.R.T. independently
for eligibility against the predefined inclusion and exclusion
criteria. A third reviewer (C.T.) was used when disagreement occurred, and consensus among the 3 reviewers was achieved.

Data Extraction
Eligibility Criteria
Studies were considered eligible and included in the review if
they met the following criteria regarding participants (P), intervention (I), comparator (C), outcomes (O), and study design (S):
P—adult men or women (age ≥18 years) diagnosed with
PanCa (stages I–IV) who were before or after surgical resection irrespective of therapy administration (such as chemotherapy, radiotherapy, and chemoradiation) or in palliative care;
I—any form of exercise training including supervised or
home-based programs with varied volumes and intensities;
C—with or without a control group undertaking standard
care or distinct exercise training from the intervention;
O—including at least pre- and postintervention measurements for one or more outcomes of interest (ie, QoL, physical
function, CRF, and psychological distress) in patients with PanCa
undertaking exercise training; and
S—all intervention-based studies including randomized controlled trials (RCTs)/nonrandomized controlled trials and uncontrolled trials.
Studies were excluded if (i) participants consisted of non-PanCa
patients unless separate data were available (however, participants
with periampullary and ampullary adenocarcinoma were considered
if they were treated similarly to those with pancreatic tumors in the
trial); (ii) intervention included only stretch activity (exercise intervention complemented by nonexercise components was considered, such as diet and/or nutritional supplements); (iii) no
data regarding the outcomes of interest were articulately reported;
or (iv) only qualitative research was conducted.

Search Strategy
Electronic searching of all available records up until January
31, 2020, was undertaken in PubMed, Web of Science, PsycINFO,
Embase, CINAHL Plus, and Cochrane Library databases using
controlled vocabulary and free-text terms (Supplemental Table 2,
http://links.lww.com/MPA/A854). Standardized thesaurus terms
for the major concepts regarding population and intervention in
each database were identified through respective subject headings
search tool. Free-text terms were developed based on the predefined
review question. All search terms and their combinations were
piloted in the selected databases to ensure retrieval of as many relevant studies as possible. No limitations were imposed on search
fields during electronic searching. In addition, a rerun of literature
searching was conducted before data extraction and synthesis to
identify any relevant late-published studies. Beyond database
searching, additional methods of literature searching were also used
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Data extraction of all included articles was performed by 2
reviewers (H.L. and P.L.) independently using a preestablished
form that was developed based on a template recommended by
the Cochrane Effective Practice and Organization of Care group.34
This form was pilot tested by H.L. to ensure all relevant information could be captured. The following data were extracted from all
included articles: general study information (such as name of the
first author, country, and year of publication), study design, study
setting, participant and intervention characteristics, data collection
methods, and outcomes of interest for each group/participant. Any
discrepancies on extracted data were resolved by discussion between
H.L. and P.L., and an agreement was achieved for all data items.

Risk of Bias (Methodological Quality) Assessment
Risk of bias assessment of all included studies was evaluated
using the McMaster University Critical Appraisal Tool (CAT) for
Quantitative Studies35 due to the diversified quantitative research
designs of the included studies. The CAT includes 14 questions
that cover the domains of study purpose, literature review, study
sample, outcome measure, intervention, results, and conclusions.
Each question was rated as “yes,” “no,” or “not addressed” depending on how well the study met the criterion of the question,
in which “yes” was conferred 1 point, whereas “no” and “not addressed” equaled 0 points (pts). A sum score was calculated for
each study based on the applicable questions in the CAT, with
higher scores indicating higher methodological quality.36–38 The
risk of bias assessment for all included studies was performed independently by 2 reviewers (H.L. and P.L.). Any disagreements
between H.L. and P.L. were resolved by consensus through discussion with a third reviewer (D.R.T.).

RESULTS
Study Selection
A total of 6498 records were identified through all sources,
and the process of study selection is shown in Figure 1. After
deduplication with EndNote, 5671 records were screened by titles
and abstracts. After removal of irrelevant records (n = 5239) and
further deduplication manually (n = 389), the full text of 43 articles were evaluated for eligibility. Of these, 34 articles were excluded based on the predefined inclusion and exclusion criteria.
No additional records were identified through a rerun of database
searching undertaken before the data extraction and synthesis.
Therefore, 9 articles39–47 based on 7 trials were finally included
www.pancreasjournal.com
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FIGURE 1. Flow diagram of study selection.

in this review, in which 2 trials41,44 reported the outcomes of interest separately in 2 articles.41,44,45,47

Risk of Bias Assessment
The risk of bias assessment of the included trials is presented
in Table 1. For trials with more than one publication included,41,44,45,47 the risk of bias was appraised based on the information provided in the first published article.41,44 In accordance
with the questions applicable to different research designs in the
McMaster CAT, there were various levels of bias in all of the included trials except for the trial by Yeo et al39 that scored 14 of
14 pts (100%). Regardless of research design, all included
trials39–47 satisfied the criteria regarding study purpose, research
justification, participants and intervention description, data analysis methods, and clinical significance. In addition, 639–45,47 of the
7 included trials scored positively in items 4a (reliability of outcome measures), 4b (validity of outcome measures), and 7 (appropriateness in conclusion). In contrast, the major methodological
concerns were observed in items 3b (justification of sample size)
and 5c (control of cointervention), which were present in 343–46
and 540–43,46,47 of the included trials, respectively.
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Study Characteristics
Study characteristics of the included publications are presented in Table 2. The findings of the included trials were published between 2012 and 2019, with 3 trials conducted in the
United States,39,41,43 2 in Germany,42,44 and 1 in Australia40 and
the United Kingdom,46 respectively. Of the 7 trials, 2 were
RCTs,39,44 1 a single-arm trial,41 3 were case reports,40,42,46 and
1 was a case series.43 In addition, the included trials were conducted either before41,43,46 or after surgery,39,40,44 except for the
case report by Niels et al,42 which was undertaken across different
settings (ie, palliative care, neoadjuvant and adjuvant settings).

Participant Characteristics
The number of participants in the case series,43 single-arm
trial, and RCTs44,45 ranged from 3 to 102 with both men and
women included, whereas each of the 3 case reports40,42,46 included only 1 male patient. In addition, the sample size involved
in the trial by Ngo-Huang et al41 differed in its 2 published articles
(ie, n = 2041 and 5047) due to further recruitment after the initial
publication. The age range of participants was 38 to
91 years.39,40,42,43,46 However, 2 trials with 4 publications41,44,45,47
only reported the mean age standard deviation (SD) of the group.
41

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1. Risk of Bias Assessment of Included Trials
Study, Year

Design 1
39

Yeo et al, 2012
Cormie et al, 201440
Ngo-Huang et al, 201741*
Ngo-Huang et al, 201947*
Niels et al, 201842
Marker et al, 201843
Wiskemann et al, 201944‡
Steindorf et al, 201945‡
McLaughlin et al, 201946

2 3a

3b

4a

4b

5a

5b

5c

RCT
CR
SAT

Y Y Y
Y Y Y
Y Y Y

Y
Y
Y

Y
Y
Y

Y
Y
Y

Y Y
Y N/A
Y N/A

Y Y
N/A Y
Y Y

Y Y Y
Y N/A Y
Y Y† Y

14/14 (100)
10/11 (91)
12/13 (92)

CR
CS
RCT

Y Y Y
Y Y Y
Y Y Y

Y
N
N§

Y
Y
Y

Y
Y
Y

Y N/A
N
N/A Y
Y N/A Not Ad N/A Y
Y Y
Y
Y Y

Y N/A Y
Y N/A Y
Y Y Y

10/11 (91)
9/11 (82)
13/14 (93)

CR

Y Y Y Not ad Not ad Not ad Y N/A Not ad N/A Y

Y N/A N

6/11 (55)

Y
N
N

6a

6b 6c

6d

7 Overall Score (%)

Item: 1: Was the purpose stated clearly? 2: Was relevant background literature reviewed? 3a: Was the sample described in detail? 3b: Was sample size
justified? 4a: Were outcome measures reliable? 4b: Were outcome measures valid? 5a: Was intervention described in detail? 5b: Was contamination
avoided? 5c: Was cointervention avoided? 6a: Were results reported in terms of statistical significance? 6b: Were the analysis method(s) appropriate? 6c:
Was clinical importance reported? 6d: Were dropouts reported? 7: Were conclusions appropriate given study methods and results?
*Same trial with different sample size involved, outcome measures and data reported.
†
The report of dropouts was not addressed in the companion paper (Ngo-Huang et al, 2019) from the same trial.
‡
Same trial with different outcome measures and data reported.
§
The justification of sample size was provided in the companion article (Steindorf et al, 2019) from the same trial.
CR indicates case report; CS, case series; N, no; N/A, not applicable; Not Ad, not addressed; SAT, single-arm trial; Y, yes.

The included trials39–44,46 comprised patients with stage I–IV
PanCa. Of them, however, only 2 patients were diagnosed with
metastatic disease, with 1 in the case report by Niels et al42 and
1 in the RCT by Wiskemann et al.44 Two trials39,44 contained 5 patients with ampullary or periampullary cancer out of a sample size
of 10239 and 43,44 respectively, including ampullary ductal, bile
duct, and duodenal adenocarcinoma. Three trials43,44,47 consisted
of patients with cancer cachexia or sarcopenia (with or without
frailty) based on relevant diagnostic criteria. Specifically, Wiskemann
et al44 reported that more than half (55.8%) of the participants were
cachectic, experiencing a weight loss of 10% or higher in the last
6 months before the baseline assessment.48 Similarly, in the case
series by Marker et al,43 2 of the 3 participants were reported as
cachectic, having a weight loss of greater than 2% and an appendicular skeletal muscle index consistent with sarcopenia.48 In addition, Ngo-Huang et al47 reported that 56% (n = 28) of the
participants were sarcopenic,49 and of these, 8 were classed as
frail (as per Fried's phenotype criteria for frailty50).

exercises in each session using machines or resistance bands that
cover the major muscle groups of the upper and lower
body.40–42,44,46 In addition, 1 to 3 sets of 6 to 20 repetitions/set
were performed for each resistance exercise at an intensity of
50% to 85% of 1 repetition maximum (1RM) or a rating of perceived exertion (RPE) of 12 to 16 (Borg 6–20 Scale).40–42,44,46
With regard to the aerobic exercise component, 8 to 20 minutes
of interval or continuous exercise training (such as walking and
cycling) were performed at an intensity of 65% to 80% of maximum heart rate or an RPE of 11 to 13.40–42,46
In addition to the exercise program, 3 trials41,43,44 offered
participants complementary nutritional support/counseling. Of
them, however, only the trial by Ngo-Huang et al41 provided a detailed description of their nutritional support that included at least
20 g of protein intake via a high-protein meal or snack within an
hour after completion of the resistance training session and guidance on food selection.

Outcomes of Interest
Intervention Characteristics
The characteristics of the exercise interventions are shown in
Table 2. Four trials40,42,43,46 offered supervised combined resistance
and aerobic exercise, 1 trial44 used supervised or home-based resistance training, and 2 trials39,41 prescribed structured home-based
walking with or without resistance training. However, in the case
reports by Cormie et al40 and McLaughlin et al,46 patients were
also encouraged to perform additional home-based aerobic exercise to supplement clinic sessions with the goal of accumulating
weekly 150 minutes of moderate-intensity or 75 minutes of
vigorous-intensity exercise.51 Moreover, in the case report by
McLaughlin et al,46 low-intensity (60% of maximum heart rate)
ergometer cycling during the 12 weeks of chemotherapy infusion
was performed.
The length of the exercise interventions ranged from 12 to
35 weeks39–42,44,46 or was reported as spanning the period of neoadjuvant therapy.43 All trials except for Yeo et al39 required participants
to exercise 2 to 3 times per week with the sessional duration of at least
60 minutes. Resistance training was reported as completing 5 to 10
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

The effects of the interventions on QoL, CRF, psychological
distress, and physical function are shown in Table 2.

Quality of Life
All included trials39,40,42,43,45–47 examined QoL using various scales. Of these trials, inconsistent findings were reported in
the RCTs39,45 and the single-arm trial.47 Yeo et al39 measured
QoL using the 36-item Short Form Health Survey (version 2.0)
(SF-36) physical component summary (PCS) and mental component summary (MCS), and reported statistically (P ≤ 0.05) and
clinically significant changes in the PCS (5 pts) and MCS (6
pts)52–54 in the exercise group. In the three-arm RCT reported by
Steindorf et al,45 the European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire Core module
(EORTC QLQ-C30) and the PanCa specific module (QLQPAN26) were used, with no significant difference observed at
the end of the 6-month study. However, at 3 months, there was a
significant difference (P = 0.016) in the QLQ-C30 global health
status/QoL scale between the pooled exercise groups and the
www.pancreasjournal.com
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Steindorf et al,
2019,45‡
Germany

Wiskemann et al,
2019,44‡
Germany

Controlled trials
Yeo et al,
2012,39
United States

Study, Year,
Country

RCT

RCT

RCT

ADJ

ADJ

ADJ

As above (see
Wiskemann et al, 2019)

Ex1: 9, M & F, 63 (6.4) y, PanCa
(78%) and bile duct, stage I–II
Ex2: 20, M & F, 61 (8.7) y, PanCa
(95%) and bile duct stage I–IV
UC: 14, M & F, 58 (8.2) y, PanCa
(86%), bile duct and ampullary
ductal, stage I–II

Ex: 54, M & F, 66 y (38–87 y),
PanCa (96%), bile duct and
duodenal, stage I–III
UC: 48, M & F, 67 y (48–91 y),
PanCa (94%), bile duct and
duodenal, stage I–III

Sample Size by
Group, Sex, Age/Mean
Study Age (SD) (Range), Type (%
Design Setting
of PanCa), and Staging

TABLE 2. Characteristics of Included Publications

Type: Walking
Length: 3 mo
Frequency: progress
to 3–5 sessions/wk
Duration: progress to
20–40 min/session
Volume: progress to
10–30 min of brisk
walking/session
Intensity: not predetermined
and untracked
Setting: home
Supervision: no
Type: resistance training
Length: 6 mo
Frequency: 2 sessions/wk
Duration: 60 min/session
Volume: 5–8 exercises,
1–3 sets/exercise with
8–20 repetitions/set
Intensity: 50%–80% of
1RM (Ex1) or an RPE
of 14–16 (Borg 6–20
scale) (Ex2)
Setting: exercise facility
(Ex1) or home (Ex2)
Supervision: yes (Ex1)
or no (Ex2)
As above (see Wiskemann
et al, 2019)

Exercise Program

– EORTC QLQ-C30
(the global health
status/QoL scale
↑11.5 pts at T1 for the
pooled Ex group);
EORTC QLQ-PAN26
(pancreatic pain:
↓10.3 pts (T1) and
↓8.3 pts (T2) for Ex2;
indigestion: ↓9.3 pts
(T1) and ↓16.7 pts (T2)
for Ex1; body image:
↓10.8 pts (T1) and
↓11.9 pts (T2) for Ex2)
– MFI (for the pooled
exercise group physical
fatigue ↓3.3 pts (T1) and
↓2.6 pts (T2), and reduced
activity ↓2.1 pts (T1)

– QoL|| ↑§(T1), ↔(T2)
– General fatigue ↔
(T1), ↔(T2); physical
fatigue ↑§(T1), ↔(T2);
mental fatigue ↔(T1),
↔(T2); reduced
activity ↑§(T1), ↔(T2);
reduced motivation
↑§(T1), ↔(T2)

– Muscle strength↑§
– Cardiovascular
fitness↔

– Isokinetic and handheld
dynamometer
– CPET (VO2max ↑0.1
L/min and ↑0.2 L/min
in Ex1 and Ex2,
respectively); 6MWT

Pre- and
postintervention

Preintervention (baseline),
3 (T1) and 6 mo (T2)

– QoL↑†
– CRF↓†

Results

– SF-36 (PCS ↑5 pts,
MCS ↑6 pts)
– FACIT-F (total score
↑9 pts); FVAS (↓1.3 pts)

Measures (Clinically
Relevant Changes)*

Postsurgery (baseline),
and 3–6 mo after
discharge

Time Points

Outcomes

As above (see Wiskemann
et al, 2019) except for
retention rate (=68%) in
Ex2 reported differently

No intervention-related AEs;
Recruitment rate: 21%,
Retention rate: 75% (Ex1)
vs 71% (Ex2) vs
77% (UC),
Attendance rate: 64% (Ex1)
vs 78% (Ex2)

No intervention-related AEs;
Recruitment rate: 93%
Retention rate: 76% (Ex)
vs 73% (UC)

Feasibility
Profile

Luo et al
Pancreas • Volume 50, Number 3, March 2021

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

Ngo-Huang et al,
2017,41#
United States

Uncontrolled trials
Cormie et al,
2014,40
Australia

SAT

CR

NAJ

ADJ

Ex: 20, M & F, 64 (9.9) y,
PanCa (100%),
potentially resectable
No control arm

Ex: 1, M, 49 y,
PanCa (100%), stage II
No control arm

Type: resistance training
(R) + walking (W)
Length: median of 17 wk
(range, 5–35 wk) over
the preoperative period
Frequency: at least 2 (R)
or 3 (W) d/wk
Duration: at least 60 min/d
Volume: (R) 8 exercises, 3 sets/
exercise, 8–12 repetitions/
set; (W) at least 20 min/d
Intensity: RPE of 12–13
(Borg 6–20 scale)
Setting: home
Supervision: no

– SF-36 (PCS ↑8.3 pts and
↑12.3 pts, MCS ↑11
pts and ↑17.9 pts at T1
and T2, respectively);
FACT-Hep (total score
↑31 pts and ↑37 pts
at T1 and T2,
respectively)
– FACIT-F (total score
↑28 pts and ↑39 pts
at T1 and T2,
respectively)
– BSI-18
– 400-m walk test (time
↓43.3 s at T2)
- Leg press 1RM test
- 5STS (time ↓2 s and
↓3.2 s at T1 and T2,
respectively)
- Stairclimb test; usualand fast-pace 6-m
walk tests
- 6-m backward walk;
Sensory Organization Test
Baseline (T0), and pre- (T1) – 10-m walk test (gait speed
and postsurgery (T2)
↑0.18 m/s at T1); Dynamic
Gait Index (total score
↑1.2 pts at T1)
– 5STS

Type: resistance (R) +
Preintervention (baseline),
aerobic (A) exercise
3 (T1) and 6 mo (T2)
Length: 6 mo
Frequency: 2 sessions/wk
Duration: 60 min/session
Volume: (R) 10 exercises,
2–3 sets/exercise; (A) 15–20
min walking and cycling
Intensity: (R) 6–12RM; (A)
65%–80% MHR with an RPE
of 11–13 (Borg 6–20 scale)
Setting: exercise clinic and home
(accumulating additional 150
min of walking and/or
cycling per wk)
Supervision: mixed¶

– Functional ambulation
↔(T1), ↔(T2);
Balance ↔(T1), ↔(T2)
– Muscle power ↔(T1),
↔(T2)

(Continued on next page)

No intervention-related AEs;
Retention rate at T1: 75%
(50% at T2 because
patients not amendable to
surgery were excluded
from postintervention
assessment)

No intervention-related AEs;
– QoL ↑(T1), ↑(T2)
Attendance rate: 73%
– CRF ↓(T1), ↓(T2)
– Psychological distress ↓
(T1), ↓(T2)
– Cardiovascular fitness ↑
(T1), ↑(T2)
– Muscle strength ↑(T1), ↑(T2)
– Muscle power ↑(T1), ↑(T2)
– Functional ambulation ↑
(T1), ↑(T2)
– Balance ↑(T1), ↑(T2)
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CR

CS

Marker et al,
2018,43
United States

McLaughlin et al,
2019,46
United Kingdom

CR

Niels et al, 2018,42
Germany

Study, Year,
Country

NAJ

NAJ

Ex: 1, M, 47 y, PanCa
(100%), stage III
No control arm

Ex: 3, M & F, 71 (1.9) y
(70–74 y), PanCa (100%),
borderline resectable
No control arm

Ex: 1, M, 46 y, PanCa
Palliative
(100%), stage IV
+ NAJ +
No control arm
ADJ

Sample Size by
Group, Sex, Age/Mean
Study Age (SD) (Range), Type (%
Design Setting
of PanCa), and Staging

TABLE 2. (Continued)

Type: resistance (R) +
aerobic (A) exercise
Length: approximately 7 mo
Frequency: 2 sessions/wk
Duration: unspecified
Volume: (R) 6 exercises,
2 sets/exercise, 8–12
repetitions/set; (A) 2 sets
of ergometer training,
4–10 min/set
Intensity: (R) 70%–80%
of 1RM; (A) 70%–80%
MHR with an RPE of
6–7 (Borg 0–10 scale)
Setting: unspecified
Supervision: yes
Type: resistance +
aerobic exercise
Length: over the
neoadjuvant therapy
Frequency: 2–3 sessions/wk
Duration: 60 min/session
Volume: 45 min of combined
aerobic and resistance
exercises
Intensity: ≤85% of heart-rate
reserve or RPE of 7
(Borg 0–10 scale)
Setting: fitness facility
Supervision: yes
Type: resistance (R) +
aerobic (A) exercise
Length: 12 wk
Frequency: 2 sessions/wk
Duration: unspecified
Volume: (R) 8 exercises,
3 sets/exercise, 12
repetitions/set; (A) 15 min
of continuous cycling
Intensity: (R) 60% of 1RM;
(A) 70% of MHR
Setting: gym, home
(accumulating additional
150-min of moderate
intensity or 75-min of
vigorous intensity exercise
per week), and hospital
(40 min of cycling during
infusion at 60% of MHR)
Supervision: mixed¶

Exercise Program

Baseline (T0), 4 (T1), 8
(T2), and 12 wk (T3)

– FACT-Hep
– FACIT-F
– BSI-18
– Submaximal Astrand test
– 12RM tests
– 5STS
– Stairclimb test; usual- and
fast-pace 6-meter walk test
– 6-m backward walk

– QoL ↑(T1), ↑(T2), ↑(T3)
– CRF ↓(T1), ↓(T2), ↓(T3)
– Psychological distress
↓(T1), ↓(T2), ↓(T3)
– Aerobic capacity ↑(T1),
↑(T2), ↑(T3)
– Muscle strength ↑(T1),
↑(T2), ↑(T3)
– Muscle power ↑(T1),
↑(T2), ↑(T3)
– Functional ambulation
↑(T1), ↑(T2), ↑(T3)
– Balance ↑(T1), ↑(T2),
↑(T3)

No intervention-related AEs;
Attendance rate: 96%
(gym-based exercise
sessions),
Program adherence rate:
100% and 69%
(gym-based exercise
sessions in
nonchemotherapy and
chemotherapy weeks,
respectively) and 83%
(cycling during infusion)

– QoL ↑(T1), ↑(T2)
Information or data regarding
– CRF ↓(T1), ↓(T2)
AEs was not provided;
– Depression ↓(T1), ↓(T2)
No. eligible patients recruited
– Cardiovascular
within 8 mo: 3;
fitness ↑(T1), ↑(T2)
Percentage of wk with at
– Functional ambulation
least 2 sessions attended
↑(T1), ↓(T2)
weekly against the total
– Muscle strength ↑(T1), ↓(T2)
wk involved: 85%
– Muscle power ↑(T1), ↑(T2)

– FACT-G (total score
↑16.5 pts and ↑12 pts at
T1 and T2, respectively)
– FACIT-F (total score
↑5 pts at T1 and T2)
– CES-D
– 400-m walk test
– Usual- and fast-pace
10-meter walk test
– Grip strength dynamometry
– 30STS (↑6 repetitions at T1)

Baseline (T0), presurgery
(T1), and 6 wk after
discharge (T2)

Feasibility
Profile

– QoL ↑(T1), ↑(T2)
No intervention-related AEs
– Depression ↓(T1), ↓(T2);
anxiety ↓(T1), ↓(T2)
– Muscle strength ↑(T1), ↑(T2)
– Cardiovascular
fitness ↑(T1), ↑(T2)

Results

– EORTC QLQ-C30 (the
global health status/QoL
↑16.6 pts at T1 and T2)
– HADS (depression subscale
score ↓3 pts and ↓4 pts at
T1 and T2, respectively)
– 1RM test (leg extension
strength ↑26.7 kg at T1 and
T2, chest press strength
↑15.6 kg and ↑17.7 kg at
T1 and T2, respectively);
– CPET (maximal cycle
excise capacity ↑35w and
↑45w at T1 and T2,
respectively)

Measures (Clinically
Relevant Changes)*

Baseline (T0), 3 (T1),
and 7 mo (T2)

Time Points

Outcomes

Luo et al
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*When there was clinical meaningfulness based on the relevant MID provided in Supplementary Table 1.
†
Statistically significant from baseline.
‡
Same trial with different outcome measures and data reported.
§
Statistically significant from control group.
||
Based on the global health status/QoL score in EORTC QLQ-C30.
¶
Supervised + unsupervised.
#
Same trial with different sample size involved, outcome measures, and data reported.
↔ indicates no statistical significance; ↑, increase; ↓, decrease; 5STS, 5-repetition sit-to-stand; 6MWT, 6-minute walk test; 30STS, 30-second sit-to-stand test; ADJ, adjuvant; BSI-18, Brief Symptom Inventory18; CES-D; Center for Epidemiologic Studies Depression Scale; CR, case report; Ex, exercise group; F, female; FACT-G, Functional Assessment of Cancer Therapy–General questionnaire; M, male; MFI, Multidimensional Fatigue Inventory; MHR, maximum heart rate; NAJ, neoadjuvant; PAN 26, pancreatic cancer specific module; SAT, single-arm trial; UC, usual care control group; VO2max, maximum oxygen uptake.

Ngo-Huang et al,
2019,47#
United States

SAT

NAJ

Ex: 50, M & F, 66 (8) y,
PanCa (100%),
potentially resectable
No control arm

As above (see Ngo-Huang
et al, 2017), except for the
length of the intervention
reported as mean duration
of 16 wk (SD, 9 wk)

Baseline and
postintervention
(before surgery)

– FACT-Hep
– 6MWT (distance ↑25.7 m)
– 5STS

– QoL↔
– Cardiovascular fitness↑†
– Muscle power↑†

No intervention-related AEs;
Retention rate: 90%
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controls,45 and the improvements exceeded the MID of 10 pts.55,56
In addition, there were clinically significant improvements in the
QLQ-PAN26 symptom scales for the supervised and home-based
exercise groups,45 including pancreatic pain (>8 pts), indigestion
(>9 pts), and body image (>10 pts).57 However, in the single-arm
trial by Ngo-Huang et al47 that used the Functional Assessment of
Cancer Therapy–Hepatobiliary (FACT-Hep) questionnaire, no
significant improvements were observed.
In the case reports40,42,46 and case series,43 positive changes
in QoL outcomes were consistently reported. Cormie et al40 used
the SF-36 and the FACT-Hep questionnaires, and clinically relevant improvements were observed in the SF-36 PCS (>8 pts)
and MCS (≥11 pts),52–54 as well as in the FACT-Hep total score
(≥31 pts).58 Niels et al42 used the QLQ-C30 with an improvement
of ~17 pts in the global health status/QoL scale, suggesting a clinically meaningful improvement in the participant's QoL.55,56 In
addition, Marker et al43 and McLaughlin et al46 assessed QoL
using the FACT-General and the FACT-Hep questionnaire, respectively. Both trials43,46 reported a numerical or percentage increase
in the total score of the questionnaire at various follow-up periods,
and the increments (≥12 pts) in the trial by Marker et al43 were of
clinical significance.59

Cancer-Related Fatigue
Five trials39,40,43,45,46 examined CRF using different scales.
Yeo et al39 used the Functional Assessment of Chronic Illness
Therapy–Fatigue (FACIT-F) scale and the Fatigue Visual Analog
Scale (FVAS, 0–10), and reported statistically (P ≤ 0.05) and clinically significant changes in the exercise group for both measures
(FACIT-F: 9 pts59; FVAS: 1.3 pts60). At the midpoint of the
6-month trial by Steindorf et al,45 there were significant group differences (P < 0.03) in various fatigue dimensions measured by the
Multidimensional Fatigue Inventory, including physical fatigue,
reduced activity, and reduced motivation. In addition, the improvements in physical fatigue (>2.5 pts) and reduced activity (>2 pts) for
the pooled exercise groups of the trial45 were clinically significant.61 In the remaining 3 trials,40,43,46 CRF was assessed using
the FACIT-F, and all reported a higher score after the exercise intervention compared with baseline, indicating a reduction in fatigue, with the magnitude of change in the trials by Cormie
et al40 (≥28 pts) and Marker et al43 (5 pts) being clinically important.59

Psychological Distress
Four trials40,42,43,46 examined variables associated with psychological distress (including anxiety, depression, and somatization) using varied questionnaires that included the Brief
Symptom Inventory-18, the Hospital Anxiety and Depression
Scale (HADS), and the Center for Epidemiologic Studies Depression Scale. All of these trials40,42,43,46 reported an improvement in
the related symptom scales across various time points, and the
change score in the depression subscale of the HADS (≥3 pts)
in the case report by Niels et al42 was clinically meaningful.62

Physical Function
A wide array of objectively-measured physical function parameters were examined in 6 trials,40–44,46,47 including muscle
strength and power, cardiovascular fitness, functional ambulation,
and balance. Five trials40,42–44,46 evaluated muscle strength using
various methods. Wiskemann et al44 used an isokinetic dynamometer and a handheld dynamometer in their 3-armed trial, with a
significant group difference (P = 0.04) in isometric strength observed for knee extension favoring the home-based exercise
group. In addition, the authors44 also reported a significantly
greater isokinetic force of elbow flexors (P = 0.02) and elbow
www.pancreasjournal.com
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extensors (P = 0.01) in the supervised exercise group compared
with controls. The remaining 4 trials40,42,43,46 used either a
1RM, a 12RM, or a grip strength test, with three40,42,46 reporting
enhanced muscle strength across various follow-up periods, and
the case report by Niels et al42 reporting a clinically relevant improvement in chest press (>15.6 kg) and leg extension (26.7 kg) strength.63
In addition, Marker et al43 in their case series of 3 patients exercising
during neoadjuvant therapy (chemotherapy and radiotherapy) reported an improvement in grip strength before surgery.
Four trials40,43,46,47 measured lower-limb muscle power
using either the 5-repetition sit-to-stand (5STS) or the 30-second
sit-to-stand test (30STS), and all reported an improvement. Within
these trials, Ngo-Huang et al47 reported a statistically significant
improvement (P = 0.049) in participants after preoperative exercise (mean duration of 16 weeks); however, the change was not
significant in their first publication,41 which involved a smaller
sample size. In addition, clinically relevant improvements were
observed in Cormie et al40 using the 5STS (time reduced ≥2 seconds)64 and in Marker et al43 using the 30STS (6 more repetitions)65 at varying time points.
All trials but one39 examined cardiovascular fitness using either a performance-based test or a laboratory test alone or in combination and reported varying magnitudes of gains. Ngo-Huang
et al47 reported a significant within-group change (P = 0.001) in
the 6-minute walk test, with the improvement of 25.7 m clinically
meaningful.66 In addition, in the 3-arm RCT by Wiskemann
et al,44 the improvement in maximal oxygen uptake for the exercise groups (0.1 and 0.2 L/min) measured by the cardiopulmonary
exercise test (CPET) also exceeded the MID of 0.05 L/min,67,68 although the gains were not statistically significant. Of the remaining
4 trials,40,42,43,46 clinically relevant improvements were observed by
Cormie et al40 using the 400-m walk test (time reduced by 43.3 seconds)69 and Niels et al42 using the CPET (>35-W improvement in
maximal cycling capacity).67,68
Four trials40,41,43,46 assessed functional ambulation using either the 10-m walk test alone or multiple tests (including stair
climb, and usual- and fast-pace 6- and 10-m walk). All of the trials40,41,43,46 reported an improvement at midpoint assessments,
and 240,46 also demonstrated gains at postintervention. In addition,
there was a clinically relevant improvement in the 10-m walk test
(0.18 m/s faster)70 in the single-arm trial by Ngo-Huang et al,41 although the change was not statistically significant.
With regard to balance ability, 3 trials40,41,46 assessed dynamic balance with either the 6-m backward walk or the Dynamic
Gait Index. In addition, Cormie et al40 also measured postural balance using the Sensory Organization Test. All trials40,41,46 demonstrated an improvement in balance, and the trial by Ngo-Huang
et al41 also showed a clinically meaningful improvement in the
Dynamic Gait Index (1.2 pts).71

Feasibility Profile
An overview of the feasibility profiles of the exercise interventions is presented in Table 2. All included trials explicitly reported no intervention-related adverse events (AEs)39–42,44–47 or
did not provide relevant description in the article.43 However,
there was a range of non–intervention-related AEs in some of
the included trials mainly due to the aggressive nature of PanCa
and treatment-related side effects. For example, multiple events
of death (n = 18) and disease progression (n = 3) were reported
in the trials by Yeo et al39 and Wiskemann et al.44 In addition,
AEs/symptoms including incisional hernia (n = 1), fracture
(n = 1), deep vein thrombosis (n = 1), constipation (n = 1), nausea
and vomiting (n = 1), and mucositis (n = 1) were reported in 3 trials.42,44,46 All of the AEs resulted in temporary or permanent
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discontinuance of the exercise programs39,42,44 or a reduction in
the prescribed exercise intensity.46
Apart from the incidence of AEs, other feasibility metrics
were provided in the included trials. Yeo et al39 and Wiskemann
et al44 reported a recruitment rate of 93% and 21%, respectively.
In addition, Marker et al43 also reported that only 3 participants
were enrolled during an 8-month recruitment period, and as a result, the study was reported as a case series. The included
RCTs39,44 and single-arm trial41 reported dropouts, and the retention
rates for the exercise groups were 76%,39 75% and 71% (for supervised and home-based exercise groups, respectively),44 and 75%41
(reported as 90% in the later published article47 from the trial). However, reasons for dropouts were only provided in the RCTs, including
death,39,44 disease progression,44 treatment-related side effects,44
further resection required,44 and withdrawal.39,44 Participants' attendance to the planned exercise sessions was reported in 3 trials,40,44,46 and the attendance rates were 73%,40 64% and 78%
(for supervised and home-based sessions, respectively),44 and
96%.46 In addition, Marker et al43 reported that for 85% of the
prescribed weeks, participants attended at least 2 sessions per
week. Only McLaughlin et al46 reported the participant's actual
completed exercise intensity, that is, 100% and 69% for supervised sessions in nonchemotherapy and chemotherapy weeks, respectively, and 83% for exercise during infusion.

DISCUSSION
This is the first systematic review examining the multifaceted
health-related effects of exercise in patients with PanCa. Given the
current evidence, exercise training seems to be safe and feasible
and may have a favorable effect on various physical and psychological outcomes in this patient group.
Despite a high number of non–intervention-related AEs, exercise training seems to be safe in patients with PanCa with no
exercise-related AEs reported across the studies. The high incidence of non–intervention-related AEs is not unexpected given
the aggressive nature of PanCa and cumulative toxicities from
cancer therapies. Importantly, the feasibility profile seemed favorable with a reported retention rate of 71% to 90% and exercise attendance of 64% to 96%. These findings are similar to a
systematic review of exercise interventions in patients with advanced cancer72 and an exercise study consisting of patients with
malignant pleural mesothelioma,73 suggesting that patients with
PanCa should not be excluded from exercise. However, the relatively short life expectancy and substantial adverse effects from
treatment regimens highlight the need for regular and shorter assessment intervals in this patient group so that the shorter-term
benefits of exercise can be determined. This may also facilitate
the necessary modifications in an exercise program being made
in a timely fashion.
Among the efficacy outcomes in current evidence, we found
that exercise training was most consistently associated with improvements in psychological distress. Combined resistance and
aerobic exercise reduced symptoms of depression and anxiety irrespective of the disease stage and study setting.40,42,43,46 This finding
is in line with several systematic reviews and meta-analyses of patients with common cancers (predominantly breast).74–76 Similarly,
a recent study in patients with pleural mesothelioma also reported
decreased anxiety after a short-term, home-based program that included resistance and aerobic exercise.73 It has been well established that exercise and, in particular, aerobic exercise are
associated with less rates of psychological distress symptoms.77,78
This may be associated with improved self-efficacy beliefs after
exercise training, which is recognized as a positive contributor
to high levels of mental health and psychological functioning.79
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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In addition, a range of biological hypotheses have been proposed for
the emotional benefits of exercise, including increase in body temperature and cerebral blood flow, and higher levels of endorphins.80
The evidence also suggests that exercise may be effective in
attenuating CRF in patients with PanCa; however, the beneficial
effect may be moderated by exercise mode. Aerobic exercise with
or without resistance training lowered fatigue levels across varying follow-up periods, whereas the improvements in various dimensions of fatigue did not persist throughout the study period
in the trial by Steindorf et al,45 which only provided resistance
training. Cancer-related fatigue is one of the most common symptoms during chemotherapy and is suggested to be influenced by
many constitutional, clinical, and environmental factors in patients with PanCa.81 There is no clear mechanistic explanation
yet regarding the role of exercise in regulating CRF during active
cancer treatment, although some reports suggest the possible association with improvements in chemotherapy-induced anemia82
and cardiorespiratory capacity83 after exercise training.
The effect of exercise on physical function seems promising.
Various improvements were observed in muscle strength and
power, cardiovascular fitness, functional ambulation, and balance.
This is generally in concordance with exercise studies in other
poor prognostic patients with cancer (including mesothelioma
and esophageal) receiving active cancer treatments, where enhanced
aerobic capacity and lower-limb muscle function were observed.73,84
The declines in muscle strength, balance, and functional ambulation
at the postsurgery assessments in the single-arm trial41 and the case
series43 may be associated with detraining and incomplete recovery
after surgery. In addition, the nonsignificant finding in 5STS in the
initial paper by Ngo-Huang et al41 is likely due to the small sample
size, as a similar improvement was reported in the subsequent report47 with a larger sample size and was statistically significant.
Regarding the effect of exercise on QoL, the current findings
are somewhat mixed. Most of the included studies demonstrated
statistically or clinically significant improvements in various
QoL scales.39,40,42,43,45,46 However, no effect was observed by
Ngo-Huang et al in their single-arm trial.47 In addition, Steindorf
et al45 only reported improvement of overall QoL at the midpoint
of their 6-month trial. The inconsistent findings in the current evidence may be explained by the complex determinants of QoL in
patients with PanCa. Evidence indicates that disease progression
is associated with a deterioration of QoL in this patient group.85
There are also a number of other factors identified that may contribute to a worsening in QoL, such as treatments, comorbidities,
and various demographic factors (including ethnicity, age, and educational level).16 Although the benefits of exercise in QoL for
various patients with cancer (including advanced disease) have
been well established,22,24,86,87 its effect for patients with PanCa
requires further work and clarification.
There are some limitations of this systematic review. First,
more than half of the trials included were uncontrolled studies,
with 3 being case reports and 1 being a case series. Thus, caution
should be taken when interpreting the findings of this review. In
addition, a meta-analysis was not undertaken as less than 2 RCTs
provided sufficient data on the same outcome measure, and the
heterogeneity in exercise programs and measurement tools/
instruments of the included studies was substantial. Lastly, the
MID values of the outcome measures in patients with PanCa were
limited, so the relevant values for patients with other cancers or clinical conditions were used to determine clinical significance. Nevertheless, the MID values used provide an indication of the
meaningfulness of the changes observed in the outcome measures.
Despite these limitations, the preliminary benefits observed
with current evidence may provide valuable insights for the management of PanCa. Of importance, the improvements in muscle
© 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
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strength and/or muscle power were reported in 3 studies,43,44,47
which consisted of a large proportion of patients with cachexia
or sarcopenia and administrated a multimodal intervention (ie, exercise training in combination with nutritional support). The disorders
of cancer cachexia and sarcopenia have been well documented leading to progressive muscle weakness and functional impairments88
and are usually difficult to treat in patients with PanCa due to their
complex pathophysiology.89
The promising initial findings warrant additional RCTs with
larger sample sizes in patients with PanCa. It is particularly important to examine the effects of exercise on cancer-related outcomes
to reinforce the role of exercise in this patient group. To date, there
is only one study published reporting exercise being associated
with normalized tumor vasculature.90 In addition, standardized
reporting of AEs in ongoing trials and, in particular, in patients
with advanced disease remains essential to confirm the safety of
exercise in patients with PanCa. It would also be worthwhile to
improve reporting of key exercise variables that are actually delivered (including volume, intensity, frequency, type, and duration)
so that compliance can be determined, which is increasingly considered pivotal in exercise oncology research.91,92 Lastly, initial
evidence suggests that sport-based programs are also associated
with various benefits in patients with cancer (mainly prostate
and breast).93 Therefore, investigating alternative physical activities other than traditional exercise training modes may prove beneficial in providing a wider array of activities in which patients
with PanCa can safely participate to derive physical and psychological benefits and enhance QoL.

CONCLUSIONS
The current evidence suggests that exercise training is safe
and feasible and has a beneficial effect on various physical and
psychological outcomes in patients with PanCa. However, as patients with PanCa are an understudied patient group in current exercise oncology research, only a small number of trials were
included in this review, with more than half of them being a case
report or case series. In addition, there was vast heterogeneity of
exercise programs and measurement instruments in the included
studies. Therefore, additional RCTs with high methodological
quality and homogeneous measurement instruments are required
to consolidate and advance our findings.
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